Pravastatin

Generic Name
Pravastatin
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C23H36O7
CAS Number
81093-37-0
Unique Ingredient Identifier
KXO2KT9N0G
Background

Pravastatin is the 6-alpha-hydroxy acid form of mevastatin. Pravastatin was firstly approved in 1991 becoming the second available statin in the United States. It was the first statin administered as the active form and not as a prodrug. This drug was developed by Sankyo Co. Ltd.; however, the first approved pravastatin product was developed by Bristol Myers...

Indication

Pravastatin is indicated for primary prevention of coronary events hypercholesterolemic patients without clinical evidence of coronary heart disease. Its use includes the reduction of risk on myocardial infarction, undergoing myocardial revascularization procedures and cardiovascular mortality.
...

Associated Conditions
Acute Coronary Events, Cardiovascular Outcomes, Coronary Artery Atherosclerosis, Death, Dysbetalipoproteinemia, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Hyperlipidemias, Mixed Dyslipidemias, Myocardial Infarction, Myocardial Revascularization, Secondary prevention cardiovascular event, Stroke, Sudden Cardiac Death, Transient Ischemic Attack, Elevation of serum triglyceride levels
Associated Therapies
-
Clinical Trials
Related News

Study to Compare the Efficacy and Safety of Pitavastatin and Pravastatin in Elderly Patients

First Posted Date
2005-11-23
Last Posted Date
2010-03-16
Lead Sponsor
Kowa Research Europe
Target Recruit Count
962
Registration Number
NCT00257686
Locations
🇳🇱

Vasculair Onderzoek Centrum Hoorn, Hoorn, Netherlands

🇩🇰

CCBR A/S, Vejle, Denmark

🇩🇰

Copenhagen University Hospital, Copenhagen, Denmark

and more 56 locations

Pravastatin for Hyperlipidaemia in HIV.

First Posted Date
2005-09-28
Last Posted Date
2006-06-09
Lead Sponsor
Kirby Institute
Target Recruit Count
40
Registration Number
NCT00227500
Locations
🇦🇺

St. Vincents Hospital, Sydney, New South Wales, Australia

Japan Statin Treatment Against Recurrent Stroke (J-STARS)

Phase 3
Completed
Conditions
Ischemic Stroke
Interventions
Drug: Pravastatin
First Posted Date
2005-09-22
Last Posted Date
2018-01-25
Lead Sponsor
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Target Recruit Count
1578
Registration Number
NCT00221104
Locations
🇯🇵

Hiroshima University, Hiroshima, Japan

Type III Dysbetalipoproteinemia

Phase 3
Completed
Conditions
Hyperlipoproteinemia Type III
First Posted Date
2005-09-22
Last Posted Date
2010-11-19
Lead Sponsor
AstraZeneca
Target Recruit Count
30
Registration Number
NCT00214604
Locations
🇿🇦

Research Site, Cape Town, South Africa

Safety and Efficacy of Pravastatin in Relapsing-remitting Multiple Sclerosis

Phase 3
Completed
Conditions
Relapsing-remitting Multiple Sclerosis
First Posted Date
2005-09-20
Last Posted Date
2016-04-28
Lead Sponsor
Nantes University Hospital
Target Recruit Count
40
Registration Number
NCT00200655
Locations
🇫🇷

Nantes University Hospital, Nantes, France

Improving Symptoms of Schizophrenia and Schizoaffective Disorder by Supplementing Medications With Pravastatin

Phase 4
Completed
Conditions
Schizophrenia
Schizoaffective Disorder
First Posted Date
2005-09-15
Last Posted Date
2008-01-15
Lead Sponsor
University of Pittsburgh
Target Recruit Count
72
Registration Number
NCT00177580
Locations
🇺🇸

Western Psychiatric Institute & Clinic, Pittsburgh, Pennsylvania, United States

Effect of Statins on Oxidative Stress and Endothelial Progenitor Cells

First Posted Date
2005-09-14
Last Posted Date
2014-09-08
Lead Sponsor
Emory University
Target Recruit Count
36
Registration Number
NCT00166036
Locations
🇺🇸

Emory University Hospital, Atlanta, Georgia, United States

Rosuvastatin Versus Pravastatin in HIV Patients Treated With Boosted Protease Inhibitors (PI) (ANRS126)

Phase 4
Completed
Conditions
Hyperlipidemia
HIV Infections
First Posted Date
2005-07-07
Last Posted Date
2011-12-22
Lead Sponsor
French National Agency for Research on AIDS and Viral Hepatitis
Target Recruit Count
86
Registration Number
NCT00117494
Locations
🇫🇷

service de Médecine Interne Hopital Hotel Dieu, Paris, France

Pravastatin, Idarubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia

Phase 1
Completed
Conditions
Leukemia
First Posted Date
2005-04-06
Last Posted Date
2010-09-21
Lead Sponsor
Fred Hutchinson Cancer Center
Registration Number
NCT00107523
Locations
🇺🇸

M.D. Anderson Cancer Center at University of Texas, Houston, Texas, United States

🇺🇸

Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Prevention of Atherosclerosis and Heart Disease in Patients With Systemic Lupus Erythematosis (SLE)

Phase 2
Completed
Conditions
Lupus
Systemic Lupus Erythematosus
First Posted Date
2003-02-14
Last Posted Date
2013-12-24
Lead Sponsor
Brigham and Women's Hospital
Target Recruit Count
150
Registration Number
NCT00054938
Locations
🇺🇸

Brigham and Women's Hospital, RBB Brigham Arthritis Center, Boston, Massachusetts, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy